Gut-brain axis metabolic pathway regulates antidepressant efficacy of albiflorin
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The gut microbiota is increasingly recognized to influence brain function through the gut-brain axis.Albiflorin, an antidepressant natural drug in China with a good safety profile, is difficult to absorb and cannot be detected in the brain after oral administration.Accordingly, the antidepressant mechanism of albiflorin in vivo has not been elucidated clearly.Methods: We identified benzoic acid as the characteristic metabolite of albiflorin in vivo and in vitro, then discovered the roles of gut microbiota in the conversion of albiflorin by carboxylesterase.Pharmacodynamic and pharmacokinetic studies were performed for the antidepressant activities of albiflorin in animals, and the efficacy of benzoic acid in inhibiting D-amino acid oxidase (DAAO) in brain was further investigated.Results: We validated that gut microbiota transformed albiflorin to benzoic acid, a key metabolite in the intestine that could cross the blood-brain barrier and, as an inhibitor of DAAO in the brain, improved brain function and exerted antidepressant activity in vivo.Intestinal carboxylesterase was the crucial enzyme that generated benzoic acid from albiflorin.Additionally, the regulatory effect of albiflorin on the gut microbiota composition was beneficial to alleviate depression.Conclusion: Our findings suggest a novel gut-brain dialogue through intestinal benzoic acid for the treatment of depression and reveal that the gut microbiota may play a causal role in the pathogenesis and treatment of the central nervous system disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diversity, stability and resilience of the human gut microbiota
Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012) · Nature · doi:10.1038/nature11550 · Cited by 5,533
Gut microbiota in health and disease
Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010) · Physiological Reviews · doi:10.1152/physrev.00045.2009 · Cited by 4,182 · cited 1×
“The increase in probiotic bacteria (such as Lactobacillus) and decrease in pathogenic bacteria (such as Parabacteroides, Oligella and Turicibacter) may improve the health of the intestinal environment, potentially enabling it to be better able to resist diseases [37, 56-59].”
BackgroundIndigenous bacteria from the gut microbiota regulate host serotonin biosynthesis
Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015) · Cell · doi:10.1016/j.cell.2015.02.047 · Cited by 3,614 · cited 1×
“In particular, recent research has proposed a new concept, called the “gut-brain axis”, which has opened up new possibilities for the treatment of central nervous system diseases [16, 17].”
Gut–brain axis: How the microbiome influences anxiety and depression
Foster, J. A., & McVey Neufeld, K.-A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.01.005 · Cited by 2,460 · cited 1×
“In particular, recent research has proposed a new concept, called the “gut-brain axis”, which has opened up new possibilities for the treatment of central nervous system diseases [16, 17].”
BackgroundCox, L. M., Yamanishi, S., Sohn, J., Alekseyenko, A. V., Leung, J. M., Cho, I., Kim, S. G., Li, H., Gao, Z., Mahana, D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.052 · Cited by 1,859 · cited 1×
“The increase in probiotic bacteria (such as Lactobacillus) and decrease in pathogenic bacteria (such as Parabacteroides, Oligella and Turicibacter) may improve the health of the intestinal environment, potentially enabling it to be better able to resist diseases [37, 56-59].”
BackgroundThe microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846
Interactions between the microbiota and pathogenic bacteria in the gut
Bäumler, A. J., & Sperandio, V. (2016) · Nature · doi:10.1038/nature18849 · Cited by 1,420 · cited 1×
“The gut microbiota is considered a “hidden organ” in the body and may be associated with the pathogenesis of various diseases, such as cardiovascular diseases, diabetes, and obesity [10-15].”
BackgroundKang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0225-7 · Cited by 1,391
O’Toole, P. W., & Jeffery, I. B. (2015) · Science · doi:10.1126/science.aac8469 · Cited by 1,202
Mental health: a world of depression
Smith, K. (2014) · Nature · doi:10.1038/515180a · Cited by 1,148
Correlation between the human fecal microbiota and depression
Naseribafrouei, A., Hestad, K., Avershina, E., Sekelja, M., Linløkken, A., Wilson, R., & Rudi, K. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12378 · Cited by 1,044
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Diet and the Intestinal Microbiome: Associations, Functions, and Implications for Health and Disease
Albenberg, L. G., & Wu, G. D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.058 · Cited by 606 · cited 1×
“The increase in probiotic bacteria (such as Lactobacillus) and decrease in pathogenic bacteria (such as Parabacteroides, Oligella and Turicibacter) may improve the health of the intestinal environment, potentially enabling it to be better able to resist diseases [37, 56-59].”
BackgroundGut microbiome and depression: what we know and what we need to know
Winter, G., Hart, R. A., Charlesworth, R. P. G., & Sharpley, C. F. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0072 · Cited by 394 · cited 1×
“Some studies have shown that the gut microbiota is closely related to the onset and treatment of depression [18-20].”
BackgroundGuilloux, J.-P., Douillard-Guilloux, G., Kota, R., Wang, X., Gardier, A. M., Martinowich, K., Tseng, G. C., Lewis, D. A., & Sibille, E. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.113 · Cited by 378 · cited 1×
“Neurotransmitter deficiencies [3], neurotrophic alterations [4], endocrine-immune system dysfunction [5], and neuroanatomical abnormalities [6] have been shown to be related to depression.”
BackgroundThe gut-brain axis: the missing link in depression
Evrensel, A., & Ceylan, M. E. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.3.239 · Cited by 338 · cited 1×
“Some studies have shown that the gut microbiota is closely related to the onset and treatment of depression [18-20].”
BackgroundGacias, M., Gaspari, S., Santos, P.-M. G., Tamburini, S., Andrade, M., Zhang, F., Shen, N., Tolstikov, V., Kiebish, M. A., Dupree, J. L., et al. (2016) · eLife · doi:10.7554/elife.13442 · Cited by 308 · cited 1×
“The transfer of Ruminococcaceae to nonobese diabetic mice modulated their social behavior [45]; and Lactobacillus, a known probiotic, was thought to improve symptoms of depression and anxiety [46].”
BackgroundTransforming berberine into its intestine-absorbable form by the gut microbiota
Feng, R., Shou, J.-W., Zhao, Z.-X., He, C.-Y., Ma, C., Huang, M., Fu, J., Tan, X.-S., Li, X.-Y., Wen, B.-Y., et al. (2015) · Scientific Reports · doi:10.1038/srep12155 · Cited by 307 · cited 1×
“As a natural medicine, berberine exerts blood lipid lowering effects mainly through the gut microbiota [55].”
BackgroundSelf-citationIndigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis
Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015) · Cell · doi:10.1016/j.cell.2015.09.017 · Cited by 150
A review of the adverse effects and safety of noradrenergic antidepressants
Whiskey, E., & Taylor, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113492027 · Cited by 64 · cited 1×
“The antidepressants currently in use include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, and serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors [7, 8].”
Background
Cited by
Gut microbiota, a new frontier to understand traditional Chinese medicines
Feng, W., Ao, H., Peng, C., & Yan, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.024 · Cited by 377
The gut microbiota–brain axis in neurological disorder
Ullah, H., Arbab, S., Tian, Y., Liu, C.-Q., Chen, Y., Qijie, L., Khan, M. I. U., Hassan, I. U., & Li, K. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1225875 · Cited by 255
Zhang, Z.-W., Gao, C.-S., Zhang, H., Yang, J., Wang, Y.-P., Pan, L.-B., Yu, H., He, C.-Y., Luo, H.-B., Zhao, Z.-X., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.032 · Cited by 139
Self-citationLv, W.-J., Wu, X.-L., Chen, W.-Q., Li, Y.-F., Zhang, G.-F., Chao, L.-M., Zhou, J.-H., Guo, A., Liu, C., & Guo, S.-N. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7902874 · Cited by 61
“Evidence from animal models and clinical studies suggests that the gut microbiome may play a crucial role in the central nervous system function [5, 6].”
Chehadi, A. C., Pereira de Lima, E., Detregiachi, C. R. P., Santos de Argollo Haber, R., Catharin, V. M. C. S., Fornari Laurindo, L., Engracia Valenti, V., Machado Galhardi, C., Tanaka, M., & Maria Barbalho, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010465 · Cited by 8
“Albiflorin, a bioactive monoterpene glycoside, demonstrates a complementary mode of action: gut microbes metabolize it into benzoic acid, which penetrates the blood–brain barrier and inhibits D-amino acid oxidase, ultimately fostering neurogenesis and reducing depressive symptoms [275,276].”
Metadata
- Authors
- Zhao, Z.-X., Fu, J., Ma, S.-R., Peng, R., Yu, J.-B., Cong, L., Pan, L.-B., Zhang, Z.-G., Tian, H., Che, C.-T., Wang, Y., & Jiang, J.-D.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 8
- Issue
- 21
- Pages
- 5945-5959
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2902379495
- Cited by
- 126
- References
- 21
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.